Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemiaMarina Konopleva, Hagop Kantarjian, Jörge E. Cortes et al.|Haematologica|2015Cited by 121